Improving patient outcomes through autoimmune testing
Neural autoantibodies specific for intracellular and plasma membrane antigens aid the diagnosis of autoimmune epilepsy, but no single antibody is specific for this diagnosis. Identifying epilepsy as autoimmune-mediated is crucial because patients may benefit from immune suppression, while traditional antiepileptic therapy may not be effective. If autoimmune dementia is misdiagnosed as an irreversible progressive neurodegenerative disorder, it may delay a correct diagnosis beyond the window of reversibility (6–12 months) and result in devastating consequences for the patient and family. An accurate diagnosis and early-initiated immunotherapy give patients the best possible outcome.
In a Mayo Clinic study of 27 patients with suspected
autoimmune epilepsy treated with immunotherapy,
81% experienced clinical improvement and 67%
became seizure free.
When to consider testing
Consider autoimmune testing for patients presenting with new-onset epilepsy with incomplete seizure control, duration of less than two years, and one or more of the following:
Our autoimmune epilepsy evaluation is part of an evolving approach to testing for autoimmune neurological disorders using phenotypic-specific evaluations that include multiple antibodies known for their disease association.
A Test in Focus
Sean Pittock, M.D., gives an overview of the epilepsy autoimmune evaluations. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.